16 September 2026 editorial review · Trial
RGB-5088 autologous CiPSC-derived islet injection in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected misreading of inclusion wording: prior organ transplant permitted, not mandatory. Removed unsupported absolute claims about all transplant recipients and all historical grafts; separate2024 case remains distinguished.
Registry: NCT06731218. Endpoint reviewed: Safety as assessed by number of subjects with adverse events (From RGB-5088 transplantation to one year later); Proportion of subjects with HbA1c ≤ 6.5% and free of severe hypoglycemic events (From 90 days to 365 days after RGB-5088 transplantation). Eligibility reviewed: Age 18 Years to 60 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Additional source access: Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.; Illuminating the future of diabetes treatment: Autologous CiPSC-derived islets take center stage..